Health Care·Life Sciences Tools & Services·$174.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.54 | N/A | +25.29% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $6.54 | N/A | +25.29% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their ability to navigate current challenges. They are optimistic about future growth opportunities despite some uncertainties.
Management highlighted strong demand for their products.
They noted ongoing challenges in the supply chain but remain focused on growth.
The team emphasized their commitment to innovation and customer service.
Thermo Fisher Scientific's strong EPS performance indicates better-than-expected profitability, which likely contributed to the stock's 1.65% increase. The lack of revenue data and guidance may leave some investors cautious, but management's positive outlook on demand and innovation suggests potential for continued growth. Overall, the earnings report reflects resilience in a challenging environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OTIS WORLDWIDE CORP
Jan 31, 2022